{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:00:06Z","timestamp":1773525606352,"version":"3.50.1"},"reference-count":93,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Leslie Dan Faculty of Pharmacy"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/14760584.2023.2250433","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T05:00:45Z","timestamp":1692766845000},"page":"749-763","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Overview of the global vaccine ecosystem"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-6046","authenticated-orcid":false,"given":"Javad","family":"Moradpour","sequence":"first","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Chit","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada"},{"name":"Medical, Medical Head for International Region Sanofi, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Besada-Lombana","sequence":"additional","affiliation":[{"name":"Medical Director, International Region, Sanofi, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Grootendorst","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/ipe.1.25056141"},{"key":"e_1_3_7_4_1","first-page":"101","volume-title":"Supplying Vaccines: An Economic Analysis Of Critical Issues","author":"Arnould R","year":"1996","unstructured":"Arnould R, DeBrock L. The application of economic theory to the vaccine market. Supplying Vaccines: An Economic Analysis Of Critical Issues (IOS Press). 1996;101\u2013131."},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz003"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq116"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1101\/162545"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113342109"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00544-9"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020266"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1017\/nie.2021.23"},{"key":"e_1_3_7_12_1","unstructured":"Coronavirus (COVID-19) Vaccinations. Our World In Data [Internet]. [cited 2022 Feb16].Available from: https:\/\/ourworldindata.org\/covid-vaccinations"},{"key":"e_1_3_7_13_1","unstructured":"Asadu C. Nigeria to reject vaccine donations with short shelf lives. Associated Press. [cited 2021 Dec 14]. https:\/\/apnews.com\/article\/coronavirus-pandemic-health-africa-nigeria-d924cab165a324604c3b93a28cc4190d"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003895"},{"key":"e_1_3_7_15_1","unstructured":"Department of Control of Neglected Tropical Diseases Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. Geneva: World Health Organization; 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240010352"},{"key":"e_1_3_7_16_1","first-page":"1619","article-title":"Bill & Melinda Gates Foundation: shaping the vaccine manufacturing ecosystem","volume":"3","author":"Shih W","year":"2019","unstructured":"Shih W. Bill & Melinda Gates Foundation: shaping the vaccine manufacturing ecosystem. Gates Open Res. 2019;3:1619.","journal-title":"Gates Open Res"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-019-03061-2"},{"key":"e_1_3_7_18_1","unstructured":"Ball P The lightning-fast quest for COVID vaccines \u2014 and what it means for other diseases. Nature [Internet]. [2020 Dec]. Available from: https:\/\/www.nature.com\/articles\/d41586-020-03626-1"},{"key":"e_1_3_7_19_1","unstructured":"Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development. Business Wire [Internet]. [2020 Apr 9]. Available from: https:\/\/www.businesswire.com\/news\/home\/20200409005405\/en\/"},{"key":"e_1_3_7_20_1","unstructured":"Policy Cures Research. G-FINDER: tracking funding for global health R&D. G-FINDER Data Portal [Internet]. [cited 2021 Oct 1]. Available from: https:\/\/gfinderdata.policycuresresearch.org\/"},{"key":"e_1_3_7_21_1","unstructured":"Adams B Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test. Fierce Biotech [Internet]. 2020 Jul 27. Available from: https:\/\/www.fiercebiotech.com\/biotech\/moderna-nabs-a-barda-billion-as-its-kickstarts-late-stage-pandemic-vaccine-test"},{"key":"e_1_3_7_22_1","unstructured":"BioNTech. BioNTech announces new collaboration to develop HIV and tuberculosis programs. 2019. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-announces-new-collaboration-develop-hiv-and"},{"key":"e_1_3_7_23_1","unstructured":"Prioritizing diseases for research and development in emergency contexts. World Health Organization (WHO) [Internet]. [cited 2022 Feb17]. Available from: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts"},{"key":"e_1_3_7_24_1","unstructured":"Better health moves humanity forward. PATH [Internet]. [cited 2022 Apr]. Available from: https:\/\/www.path.org\/about\/"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.173187"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1356495"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-35761-6.00004-3"},{"key":"e_1_3_7_28_1","unstructured":"U.S. Department of Health & Human Services. Influenza vaccine development programs. Medical Countermeasures [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.medicalcountermeasures.gov\/barda\/influenza-and-emerging-infectious-diseases\/influenza-vaccine-development-programs\/"},{"key":"e_1_3_7_29_1","unstructured":"Universal Influenza Vaccine Research. National Institute of Allergy and Infectious Diseases [Internet]. [cited2022 Feb 17]. Available from: https:\/\/www.niaid.nih.gov\/diseases-conditions\/universal-influenza-vaccine-research"},{"key":"e_1_3_7_30_1","unstructured":"Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19. Business Wire [Internet]. [cited 2020 Jul 26]. Available from: https:\/\/www.businesswire.com\/news\/home\/20200726005025\/en\/"},{"key":"e_1_3_7_31_1","unstructured":"How we work. Bill & Melinda Gates Foundation [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.gatesfoundation.org\/about\/how-we-work"},{"key":"e_1_3_7_32_1","unstructured":"Who we are. Wellcome [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/wellcome.org\/who-we-are"},{"key":"e_1_3_7_33_1","unstructured":"Somauroo J Malaria vaccine 30 years and $1 billion in the making now deployed in third country. Forbes [Internet]. [cited 2019 Sep 24]. Available from: https:\/\/www.forbes.com\/sites\/jamessomauroo\/2019\/09\/24\/malaria-vaccine-30-years-and-1-billion-in-the-making-now-deployed-in-third-country\/?sh=96d57ce2583f"},{"key":"e_1_3_7_34_1","unstructured":"A global coalition for a global problem. CEPI [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/cepi.net\/about\/whoweare\/"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1172162"},{"key":"e_1_3_7_36_1","unstructured":"Government Sanofi officials unveil $925M in vaccine funding in Toronto. CBC News [Internet]. [cited 2021 Mar31]. Available from: https:\/\/www.cbc.ca\/news\/canada\/toronto\/flu-vaccine-production-north-york-toronto-sanofi-1.5970870"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00140-6"},{"key":"e_1_3_7_38_1","unstructured":"World Health Organization. COVID-19 vaccines with WHO emergency use listing. https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued"},{"key":"e_1_3_7_39_1","unstructured":"U.S. Department of Health & Human Services. International influenza vaccine manufacturing capacity building program. Medical Countermeasures [Internet]. [cited 2022 Feb]. Available from: https:\/\/www.medicalcountermeasures.gov\/barda\/influenza-and-emerging-infectious-diseases\/international-influenza-vaccine-manufacturing-capacity-building-program\/"},{"key":"e_1_3_7_40_1","unstructured":"Surveillance in emergencies. World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.who.int\/emergencies\/surveillance"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.17226\/9869"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.64488"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-803678-5.00517-8"},{"key":"e_1_3_7_44_1","unstructured":"Nationally Notifiable Diseases. Centers For Disease Control And Prevention (CDC) [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.cdc.gov\/healthywater\/statistics\/surveillance\/notifiable.html"},{"key":"e_1_3_7_45_1","unstructured":"European Medicines Agency (EMA). Risk management plans. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/pharmacovigilance\/risk-management\/risk-management-plans"},{"key":"e_1_3_7_46_1","unstructured":"Centers for Disease Control and Prevention. Vaccine safety datalink (VSD). https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html"},{"key":"e_1_3_7_47_1","volume-title":"Definitions and applications of terms for vaccine pharmacovigilance","author":"CIOMS\/WHO Working Group on Vaccine Pharmacovigilance","year":"2012","unstructured":"CIOMS\/WHO Working Group on Vaccine Pharmacovigilance. Definitions and applications of terms for vaccine pharmacovigilance. Geneva: The Council for International Organizations of Medical Sciences (CIOMS); 2012."},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-06668-9.50020-X"},{"key":"e_1_3_7_49_1","unstructured":"Where We Work. In: Centers for Disease Control and Prevention (CDC) [Internet]. [cited 2022 Feb17]. Available from: https:\/\/www.cdc.gov\/globalhivtb\/where-we-work\/index.html"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap7463"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.26.4.1069"},{"key":"e_1_3_7_52_1","unstructured":"International Health Regulations. In: World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.who.int\/health-topics\/international-health-regulations#tab=tab_1"},{"key":"e_1_3_7_53_1","unstructured":"Public health surveillance for COVID-19: interim guidance. World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-SurveillanceGuidance-2022.1"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.027"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.105"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/09685332211002594"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.084"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.030"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.037"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6950e2"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm695152e1"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.05.046"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czz027"},{"key":"e_1_3_7_64_1","unstructured":"World Health Organization (WHO). Regional technical advisory groups on immunization (RITAG). World Health Organization (WHO) [Internet]. [cited 2023 Feb 8] Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/regional-technical-advisory-groups-on-immunization-(ritag)"},{"key":"e_1_3_7_65_1","unstructured":"WHO Lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. World Health Organization (WHO) [Internet]. [cited 2021 May 7]. Available from: https:\/\/www.who.int\/news\/item\/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.17742\/IMAGE.IN.11.2.9"},{"key":"e_1_3_7_67_1","unstructured":"Vaccine Development\u2014101. In: US Food and Drug Administration [Internet]. [cited 2022 Feb17]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/vaccine-development-101"},{"key":"e_1_3_7_68_1","unstructured":"Partnerships and Collaboration. US Food And Drug Administration [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.fda.gov\/international-programs\/partnerships-and-collaboration"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-0090-5.00019-7"},{"key":"e_1_3_7_70_1","unstructured":"World Health Organization (WHO). AVAREF overview. World Health Organization (WHO) [Internet]. [cited 2023 Feb 8]. Available from: https:\/\/www.afro.who.int\/health-topics\/immunization\/avaref\/overview"},{"key":"e_1_3_7_71_1","unstructured":"Mission: Harmonisation for Better Health. International Council For Harmonisation (ICH) [Internet]. [cited 2022 Feb 17] Available from: https:\/\/www.ich.org\/page\/mission"},{"key":"e_1_3_7_72_1","unstructured":"World Health Organization (WHO). WHO-Listed authority (WLA). [cited 2023 Mar 23]. Available from: https:\/\/www.who.int\/initiatives\/who-listed-authority-reg-authorities"},{"key":"e_1_3_7_73_1","unstructured":"Welcome to Vaccines Prequalification. World Health Organization (WHO) [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/extranet.who.int\/pqweb\/vaccines"},{"key":"e_1_3_7_74_1","unstructured":"Medicines for use outside the European Union. European Medicines Agency [Internet]. [cited 2022 Feb 17].Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/medicines-use-outside-european-union"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00457"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1086\/420748"},{"key":"e_1_3_7_77_1","unstructured":"About the Vaccines for Children Program (VFC). Centers For Disease Control And Prevention (CDC) [Internet]. [cited 2022 Apr6]. Available from: https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/about\/index.html"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.103"},{"key":"e_1_3_7_79_1","unstructured":"Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna. U.S. Department Of Health And Human Services (HHS) [Internet]. [cited 2022 Apr 6]. Available from: https:\/\/www.hhs.gov\/about\/news\/2021\/02\/11\/biden-administration-purchases-additional-doses-covid-19-vaccines-from-pfizer-and-moderna.html"},{"key":"e_1_3_7_80_1","unstructured":"PAHO Revolving Fund. Pan American Health Organization (PAHO) [Internet]. [cited 2022 Feb17]. Available from: https:\/\/www.paho.org\/en\/revolvingfund"},{"key":"e_1_3_7_81_1","unstructured":"COVAX. Gavi [Internet]. [cited 2022 Feb 17].Available: https:\/\/www.gavi.org\/covax-facility?gclid=Cj0KCQjwwNWKBhDAARIsAJ8HkhdpvIUKB83PXcyP5vzZkDDTrQcxhftCAJ1SBBBvjjJOhJvm3WAbzxEaAm60EALw_wcB"},{"key":"e_1_3_7_82_1","unstructured":"COVAX: ensuring global equitable access to COVID-19 vaccines. UNICEF [Internet]. [cited 2022 Apr]. Available from: https:\/\/www.unicef.org\/supply\/covax-ensuring-global-equitable-access-covid-19-vaccines"},{"key":"e_1_3_7_83_1","unstructured":"de Bolle M COVAX is failing to halt the COVID-19 pandemic: here\u2019s why and how to fix it. The Conversation [Internet]. [cited 2021 Jun 8]. Available from: https:\/\/theconversation.com\/covax-is-failing-to-halt-the-covid-19-pandemic-heres-why-and-how-to-fix-it-162146"},{"key":"e_1_3_7_84_1","unstructured":"Ducharme J COVAX was a great idea but is now 500 million doses short of its vaccine distribution goals. What Exactly went wrong? Time[Internet]. 2021. https:\/\/time.com\/6096172\/covax-vaccines-what-went-wrong\/"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-022-00801-z"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60478-9"},{"key":"e_1_3_7_87_1","unstructured":"Immunization. UNICEF [Internet]. [cited 2022 Feb17]. Available from: https:\/\/www.unicef.org\/immunization"},{"key":"e_1_3_7_88_1","unstructured":"Anyiam-Osigwe T. The long view: keeping vaccines cool with cold chain. Gavi [Internet]. [2021 May 31]. Available from: https:\/\/www.gavi.org\/vaccineswork\/long-view-keeping-vaccines-cool-cold-chain?gclid=CjwKCAjwy7CKBhBMEiwA0Eb7agfoM7WSBp-sKmrDHHjfGLtG8g1Ri2aI_jIbgcjaaksF1xrO3HeXCBoCFsYQAvD_BwE"},{"key":"e_1_3_7_89_1","unstructured":"Africa Centres for Disease Control and Prevention (Africa CDC). African vaccine acquisition trust delivers 12 000 doses of COVID-19 vaccine to the african union. 2021. https:\/\/africacdc.org\/news-item\/african-vaccine-acquisition-trust-delivers-12-000-doses-of-covid-19-vaccine-to-the-african-union\/"},{"key":"e_1_3_7_90_1","unstructured":"The african union\u2019s african vaccine acquisition trust (AVAT) initiative. UNICEF [Internet]. [cited 2022 Feb 17]. Available from: https:\/\/www.unicef.org\/supply\/african-unions-african-vaccine-acquisition-trust-avat-initiative"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31558-0"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.036"},{"key":"e_1_3_7_93_1","unstructured":"World Health Organization (WHO). Ten Threats to global health in 2019. 2019. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019"},{"key":"e_1_3_7_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033245"},{"key":"e_1_3_7_95_1","volume-title":"International regulatory Harmonization amid globalization of Drug development: workshop summary","author":"Forum on Drug Discovery, Development, andTranslation, Board on Health Sciences Policy, Institute of Medicine (IOM)","year":"2013","unstructured":"Forum on Drug Discovery, Development, andTranslation, Board on Health Sciences Policy, Institute of Medicine (IOM). International regulatory Harmonization amid globalization of Drug development: workshop summary. Weisfeld V, Lustig TA, editors. (WA) (DC): National Academies Press (US); 2013."}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2023.2250433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T17:24:39Z","timestamp":1701883479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2023.2250433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/14760584.2023.2250433"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2023.2250433","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}